ArticleBiotechnology reports (Amsterdam, Netherlands)2025
Structural and functional properties of neodymium-doped hydroxyapatite nanoparticles for biomedical applications.
Article in Biotechnology reports (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neodymium (Nd³⁺) doped hydroxyapatite nanoparticles (Han: Nd³⁺ NPs) were synthesized and systematically characterized to evaluate their structural and functional properties for biomedical applications. X-ray diffraction (XRD) confirmed the crystalline phase retention post-doping, while x-ray photoelectron spectroscopy (XPS) revealed the successful incorporation of Nd³⁺ ions. The doping altered the optical and electronic properties, potentially enhancing bioactivity and imaging capabilities. Preliminary cytotoxicity assessments on MCF7 and 4T1 breast cancer cell lines indicated dose-dependent effects, with IC50 values of 36.13 µg/mL and 64.38 µg/mL, respectively. The study concludes that Han: Nd³⁺ NPs offer promise as multifunctional platforms for cytotoxic response and structural stability, with potential for future application in imaging and targeted breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.